Abstract:Multiple myeloma (MM) is a clonal proliferative tumor of plasma cells that occurs mainly in middle-aged and elderly individuals. Multiple myeloma accounts for 1% of oncologic diseases and is the second most common hematologic malignancy. It is characterized by a series of complex genetic changes that lead to the transformation of plasma cells into tumors. Patients typically present with anemia, bone pain, osteolytic destruction, renal insufficiency, and recurrent infections. [ 1 ] New treatments continue to emerge, and patient survival rates have improved dramatically, but a proportion of patients have poor outcomes and are classified as having high-risk disease. In clinical practice, patients are assessed for risk stratification through genomic profiling at the time of diagnosis as well as through test markers to mitigate the patient's disease with a targeted treatment plan based on the patient's risk stratification. [ 2 ] Patients with high-risk stratification had significantly lower survival rates and required early and effective treatment. Therefore, accurate patient stratification is important in the diagnosis and treatment of MM. Laboratory markers can assist in the selection and optimization of treatment, predict clinical outcomes, and suggest the effectiveness of targeted therapies.

Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma